Aquestive Therapeutics (AQST) Stock Forecast & Price Target

Compare

2,446 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AQST Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Aquestive

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AQST Stock 12 Month Forecast

Average Price Target

$8.83

▲(115.37% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Aquestive Therapeutics in the last 3 months. The average price target is $8.83 with a high forecast of $12.00 and a low forecast of $6.00. The average price target represents a 115.37% change from the last price of $4.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","4":"$4","7":"$7","10":"$10","13":"$13"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4,7,10,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.1,4.707692307692307,5.315384615384615,5.923076923076923,6.530769230769231,7.138461538461538,7.746153846153846,8.353846153846154,8.961538461538462,9.569230769230769,10.176923076923078,10.784615384615385,11.392307692307693,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.1,4.463846153846154,4.827692307692307,5.191538461538461,5.555384615384615,5.919230769230769,6.283076923076923,6.646923076923077,7.010769230769231,7.374615384615384,7.7384615384615385,8.102307692307694,8.466153846153846,{"y":8.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.1,4.246153846153846,4.392307692307692,4.538461538461538,4.684615384615384,4.8307692307692305,4.976923076923077,5.123076923076923,5.269230769230769,5.415384615384616,5.561538461538461,5.707692307692308,5.853846153846154,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.02,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.82,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.83,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.88,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.82,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.46,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 51, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$12.00

Average Price Target$8.83

Lowest Price Target$6.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ram Selvaraju

H.C. Wainwright

$10

Buy

143.90%

Upside

Reiterated

02/03/26

Reaffirming Buy on Anaphylm: Navigable FDA CRL, Limited Incremental Costs, and Intact 2027 Approval Timeline

Thomas Flaten

Lake Street

$8→$6

Buy

46.34%

Upside

Reiterated

02/02/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Aquestive Therapeutics (NASDAQ: AQST) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP)

Andreas Argyrides

Oppenheimer

Buy

―

Reiterated

02/02/26

Aquestive CRL from FDA 'clearing event,' says OppenheimerAquestive CRL from FDA 'clearing event,' says Oppenheimer

Roanna Ruiz

Leerink Partners

Buy

―

Reiterated

02/02/26

Buy Rating Maintained on Aquestive Therapeutics as FDA CRL Seen as Operational Setback with Manageable Risk and Attractive Long‑Term Risk‑Reward

Francois Brisebois

LifeSci Capital

$8→$9

Buy

119.51%

Upside

Reiterated

02/02/26

Buy Rating Reaffirmed on Aquestive Therapeutics as Operational FDA Setbacks De-Risk Anaphylm’s Path to Approval

James Molloy

Alliance Global Partners

$12

Buy

192.68%

Upside

Reiterated

02/02/26

Analysts' Top Healthcare Picks: Aquestive Therapeutics (AQST), Skye Bioscience (SKYE)

Kristen Kluska

Cantor Fitzgerald

Buy

95.12%

Upside

Reiterated

01/13/26

Cantor Fitzgerald Remains a Buy on Aquestive Therapeutics (AQST)

David Amsellem

Piper Sandler

$5→$8

Buy

95.12%

Upside

Reiterated

11/07/25

Aquestive Therapeutics price target raised to $8 from $5 at Piper SandlerAquestive Therapeutics price target raised to $8 from $5 at Piper Sandler

Jason Butler

Citizens JMP

$9→$12

Buy

192.68%

Upside

Reiterated

10/09/25

Aquestive Therapeutics price target raised to $12 from $9 at Citizens JMPAquestive Therapeutics price target raised to $12 from $9 at Citizens JMP

Gary Nachman

Raymond James

Buy

70.73%

Upside

Reiterated

06/17/25

Aquestive Therapeutics (AQST) Gets a Buy from Raymond James

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ram Selvaraju

H.C. Wainwright

$10

Buy

143.90%

Upside

Reiterated

02/03/26

Reaffirming Buy on Anaphylm: Navigable FDA CRL, Limited Incremental Costs, and Intact 2027 Approval Timeline

Thomas Flaten

Lake Street

$8→$6

Buy

46.34%

Upside

Reiterated

02/02/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Aquestive Therapeutics (NASDAQ: AQST) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP)

Andreas Argyrides

Oppenheimer

Buy

―

Reiterated

02/02/26

Aquestive CRL from FDA 'clearing event,' says OppenheimerAquestive CRL from FDA 'clearing event,' says Oppenheimer

Roanna Ruiz

Leerink Partners

Buy

―

Reiterated

02/02/26

Buy Rating Maintained on Aquestive Therapeutics as FDA CRL Seen as Operational Setback with Manageable Risk and Attractive Long‑Term Risk‑Reward

Francois Brisebois

LifeSci Capital

$8→$9

Buy

119.51%

Upside

Reiterated

02/02/26

Buy Rating Reaffirmed on Aquestive Therapeutics as Operational FDA Setbacks De-Risk Anaphylm’s Path to Approval

James Molloy

Alliance Global Partners

$12

Buy

192.68%

Upside

Reiterated

02/02/26

Analysts' Top Healthcare Picks: Aquestive Therapeutics (AQST), Skye Bioscience (SKYE)

Kristen Kluska

Cantor Fitzgerald

Buy

95.12%

Upside

Reiterated

01/13/26

Cantor Fitzgerald Remains a Buy on Aquestive Therapeutics (AQST)

David Amsellem

Piper Sandler

$5→$8

Buy

95.12%

Upside

Reiterated

11/07/25

Aquestive Therapeutics price target raised to $8 from $5 at Piper SandlerAquestive Therapeutics price target raised to $8 from $5 at Piper Sandler

Jason Butler

Citizens JMP

$9→$12

Buy

192.68%

Upside

Reiterated

10/09/25

Aquestive Therapeutics price target raised to $12 from $9 at Citizens JMPAquestive Therapeutics price target raised to $12 from $9 at Citizens JMP

Gary Nachman

Raymond James

Buy

70.73%

Upside

Reiterated

06/17/25

Aquestive Therapeutics (AQST) Gets a Buy from Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Aquestive Therapeutics

3 Months

xxx

Success Rate

11/17 ratings generated profit

Average Return

+21.08%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +21.08% per trade.

1 Year

Jason ButlerCitizens JMP

Success Rate

27/35 ratings generated profit

Average Return

+58.26%

reiterated a buy rating 4 months ago

Copying Jason Butler's trades and holding each position for 1 Year would result in 77.14% of your transactions generating a profit, with an average return of +58.26% per trade.

2 Years

xxx

Success Rate

10/13 ratings generated profit

Average Return

+107.87%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 76.92% of your transactions generating a profit, with an average return of +107.87% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AQST Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AQST has received 8 Buy Ratings, 43 Hold Ratings, and 10 Sell Ratings. AQST average Analyst price target in the past 3 months is 8.83.

Each month's total comprises the sum of three months' worth of ratings.

AQST Financial Forecast

AQST Earnings Forecast

Next quarter’s earnings estimate for AQST is -$0.13 with a range of -$0.16 to -$0.10. The previous quarter’s EPS was -$0.14. AQST beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year AQST has Performed in-line its overall industry.

AQST Sales Forecast

Next quarter’s sales forecast for AQST is $13.29M with a range of $11.40M to $14.30M. The previous quarter’s sales results were $12.81M. AQST beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year AQST has Performed in-line its overall industry.

AQST Stock Forecast FAQ

What is AQST’s average 12-month price target, according to analysts?

Based on analyst ratings, Aquestive Therapeutics’s 12-month average price target is 8.83.

What is AQST’s upside potential, based on the analysts’ average price target?

Aquestive Therapeutics has 115.37% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AQST a Buy, Sell or Hold?

Aquestive Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Aquestive Therapeutics’s price target?

The average price target for Aquestive Therapeutics is 8.83. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $6.00. The average price target represents 115.37% Increase from the current price of $4.1.

What do analysts say about Aquestive Therapeutics?

Aquestive Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of AQST?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Aquestive Therapeutics (AQST) Stock Forecast & Price Target

AQST Analyst Ratings

AQST Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Aquestive Therapeutics

AQST Analyst Recommendation Trends

AQST Financial Forecast

AQST Earnings Forecast

AQST Sales Forecast

AQST Stock Forecast FAQ

Detailed List of Analyst Forecasts